Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neocortical cholinergic neurons in elderly people.

P White, C R Hiley, M J Goodhardt

    Lancet (London, England)
    |March 26, 1977
    PubMed
    Summary

    Researchers studied brain tissue from normal and demented individuals to understand Alzheimer's disease. They found reduced cholinergic markers in Alzheimer's, suggesting anticholinesterase drugs may help early-stage patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Theory analysis of the Dental Hygiene Human Needs Conceptual Model.

    International journal of dental hygiene·2016
    Same author

    Characterization of calcium signals provoked by lysophosphatidylinositol in human microvascular endothelial cells.

    Physiological research·2015
    Same author

    Mechanisms of vasorelaxation induced by the cannabidiol analogue compound O-1602 in the rat small mesenteric artery.

    European journal of pharmacology·2015
    Same author

    The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

    British journal of pharmacology·2015
    Same author

    Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

    Psychopharmacology·2007
    Same author

    Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

    British journal of pharmacology·2007

    Area of Science:

    • Neuroscience
    • Gerontology
    • Neuropathology

    Background:

    • The cholinergic system plays a crucial role in cognitive function.
    • Age-related cognitive decline and dementia involve alterations in neurotransmitter systems.
    • Understanding changes in the cholinergic system is vital for developing effective dementia treatments.

    Purpose of the Study:

    • To investigate changes in presynaptic and postsynaptic cholinergic markers in the aging brain.
    • To differentiate cholinergic system alterations in various forms of dementia, including Alzheimer's disease and Pick's disease.
    • To evaluate the potential therapeutic implications of these findings for dementia treatment.

    Main Methods:

    • Measurement of choline acetyltransferase activity (presynaptic marker) in post-mortem brain tissue.

    Related Experiment Videos

  • Assessment of high-affinity binding of cholinergic antagonists (postsynaptic marker) in brain tissue.
  • Comparison of marker levels between mentally normal elderly individuals and patients with different types of dementia.

    • Main Results:

    • Muscarinic receptor binding sites in the frontal cortex decreased with age, specifically in individuals without significant senile degeneration.
    • Preliminary data indicated reduced receptor binding sites in the temporal lobe in Pick's disease.
    • Cholinergic markers were not significantly reduced in mixed senile and vascular dementia.
    • Non-vascular senile dementia of the Alzheimer type showed selective depletion of the presynaptic marker.

    Conclusions:

    • Alzheimer's disease, particularly the non-vascular senile form, is characterized by selective depletion of presynaptic cholinergic markers.
    • The findings suggest that centrally acting anticholinesterase agents could be beneficial, especially in the early stages of Alzheimer's disease.
    • Further research into cholinergic system deficits may lead to targeted therapeutic strategies for dementia.